New US user fees for the medical device, generic drug and groceryindustries are unlikely, say Republican lawmakers. House appropriations subcommittee chairman Joe Skeen feels it would be very difficult to get the fees passed, but a spokesman for Representative Skeen told the Marketletter that this does not affect the expected reauthorization of the Prescription Drug User Fee Act.
Lawmakers have generally opposed large-scale user fees since the idea first came up over 10 years ago. Several members of the committee, which has jurisdiction over the Food and Drug Administration budget, called the Clinton plan for user fees for these industries a "hidden tax," devised to help balance the budget over the next five years. If the fees were adopted, the issue would probably become tied up in a tangle of lawsuits by industries that do not want them, says Rep Skeen.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze